TABLE 1 GLOBAL CRPC MARKET,MODERATE GROWTH SCENARIO, BY GEOGRAPHY, 2020-2025 ($MILLION)
TABLE 2 GLOBAL CRPC MARKET, RAPID GROWTH SCENARIO, BY GEOGRAPHY, 2020-2025, ($MILLION)
TABLE 3 GLOBAL CRPC MARKET, DIMINISHING GROWTH SCENARIO, BY GEOGRAPHY, 2020-2025, ($MILLION)
TABLE 4 CLINICAL AND NON-CLINICAL ATTRIBUTES OF XTANDI AND ZYTIGA
TABLE 5 REIMBURSEMENT PATTERN OF CRPC DRUGS
TABLE 6 COMPETITIVE INTELLIGENCE OF DRUG INNOVATORS
TABLE 7 REIMBURSEMENT PATTERN OF CRPC DRUGS
TABLE 8 MARKET SHARE AND REVENUE OF CRPC DRUG INNOVATORS
TABLE 9 LOOMING OFF-PATENTS OF CRPC DRUGS
TABLE 10 FDA APPROVED TREATMENTS FOR CPRC AND THEIR SURVIVAL BENEFITS
TABLE 11 EMERGING PIPELINE AND IN-LINE EXTENSIONS FOR CPRC
TABLE 12 REIMBURSEMENT AND FDA APPROVAL FOR CPRC DRUGS
TABLE 13 PIPELINE FOR CPRC DRUGS
TABLE 14 GLOBAL CRPC MARKET, BY THERAPY TYPES, 2014-2020, ($MILLION)
TABLE 15 HORMONAL THERAPY DRUGS AND THEIR REVENUES IN 2014
TABLE 16 GLOBAL HORMONAL THERAPY PRODUCTS MARKET, BY TYPE, 2014-2020, ($MILLION)
TABLE 17 GLOBAL HORMONAL THERAPY DRUGS MARKET, BY GEOGRAPHY, 2014-2020, ($MILLION)
TABLE 18 CHEMOTHERAPY DRUGS AND THEIR REVENUES IN 2014
TABLE 19 GLOBAL CHEMOTHERAPY DRUG MARKET, BY TYPE, 2014-2020, ($MILLION)
TABLE 20 GLOBAL CHEMOTHERAPY DRUGS MARKET, BY GEOGRAPHY, 2014-2020, ($MILLION)
TABLE 21 IMMUNOTHERAPY DRUGS AND THEIR REVENUES IN 2014
TABLE 22 GLOBAL IMMUNOTHERAPY DRUG MARKET, BY TYPE, 2014-2020, ($MILLION)
TABLE 23 GLOBAL IMMUNOTHERAPY DRUGS MARKET, BY GEOGRAPHY, 2014-2020, ($MILLION)
TABLE 24 RADIOTHERAPY DRUGS AND THEIR REVENUES IN 2014
TABLE 25 GLOBAL RADIOTHERAPY DRUG MARKET, BY TYPE, 2014-2020, ($MILLION)
TABLE 26 GLOBAL RADIOTHERAPY DRUGS MARKET, BY GEOGRAPHY, 2014-2020, ($MILLION)
TABLE 27 GLOBAL ORAL THERAPY MARKET, BY GEOGRAPHY, 2014-2020, ($MILLION)
TABLE 28 GLOBAL INJECTABLE THERAPY MARKET, BY GEOGRAPHY, 2014-2020, ($MILLION)
TABLE 29 GLOBAL CRPC MARKET, BY GEOGRAPHY, 2014-2020, ($MILLION)
TABLE 30 CRPC TREATMENTS APPROVED IN UNITED STATES
TABLE 31 NORTH AMERICA CRPC MARKET, BY THERAPY TYPES, 2014 - 2020, ($MILLION)
TABLE 32 HIGH INCIDENCE RATES AT DIAGNOSIS IN EU-5 NATIONS AS COMPARED TO UNITED STATES
TABLE 33 EUROPE CRPC MARKET, BY THERAPY TYPES, 2014 - 2020, ($MILLION)
TABLE 34 CRPC TREATMENTS AVAILABLE AND CONSIDERATION FACTORS IN ASIA PACIFIC REGION
TABLE 35 HIGH INCIDENCE RATES AT DIAGNOSIS IN ASIA PACIFIC REGION RESULT OF LOW PSA SCREENING
TABLE 36 ASIA PACIFIC CRPC MARKET, BY THERAPY TYPES, 2014 - 2020, ($MILLION)
TABLE 37 INCIDENCE AND DEATHS FROM PROSTATE CANCER IN LATIN AMERICA
TABLE 38 LAMEA CRPC MARKET, BY THERAPY TYPES, 2014 - 2020, ($MILLION)
TABLE 39 COMPANY SNAPSHOT OF JOHNSON & JOHSNON
TABLE 40 JOHNSON & JOHSNON OPERATING SEGMENTS
TABLE 41 COMPANY SNAPSHOT OF DENDREON CORPORATION
TABLE 42 DENDREON CORPORATION OPERATING SEGMENTS
TABLE 43 COMPANY SNAPSHOT OF SANOFI
TABLE 44 SANOFI OPERATING SEGMENTS
TABLE 45 COMPANY SNAPSHOT OF BAYER
TABLE 46 BAYER OPERATING SEGMENTS
TABLE 47 COMPANY SNAPSHOT OF ASTELLAS
TABLE 48 ASTELLAS OPERATING SEGMENTS
LIST OF FIGURE
FIG. 1 IMPACT ANALYSIS OF GLOBAL CRPC MARKET IN MODERATE GROWTH SCENARIO
FIG. 2 IMPACT ANALYSIS OF GLOBAL CRPC MARKET IN RAPID GROWTH SCENARIO
FIG. 3 IMPACT ANALYSIS OF GLOBAL CRPC MARKET IN DIMINISHING GROWTH SCENARIO
FIG. 4 GLOBAL HORMONE REFRACTORY PROSTATE CANCER (HRPCA) MARKET DEFINITION
FIG. 5 EVOLUTION OF CRPC TREATMENT REGIME
FIG. 6 NON-METASTATIC CRPC MARKET PERSPECTIVE
FIG. 7 PRE-CHEMO AND POST-CHEMO CRPC MARKET POTENTIAL
FIG. 8 DETAILED MARKET OUTLOOK OF XTANDI VS. ZYTIGA
FIG. 9 TOP IMPACTING FACTORS
FIG. 10 TOP INVESTMENT POCKETS
FIG. 11 TOP WINNING STRATEGIES PERCENTAGE DISTRIBUTION
FIG. 12 TOP WINNING STRATEGIES: NATURE AND TYPE
FIG. 13 TYPES OF STRATEGIES DISTRIBUTION
FIG. 14 TOP COMPANIES AND THEIR STRATEGIES
FIG. 15 DETAILED STRUCTURE OF COMPANIES AND TYPE OF STRATEGIES
FIG. 16 DETAILED STRUCTURE OF COMPANIES AND NATURE OF STRATEGIES
FIG. 17 PORTER€™S FIVE FORCE ANALYSIS
FIG. 18 MARKET SHARE ANALYSIS (2014)
FIG. 19 VALUE CHAIN ANALYSIS BY COMPANIES
FIG. 20 VALUE CHAIN ANALYSIS BY PRODUCT
FIG. 21 MANUFACTURING PROCESS OF ZYTIGA
FIG. 22 MARKET DYNAMICS SNAPSHOT
FIG. 23 AVERAGE NUMBER OF DEATHS PER YEAR AND AGE-SPECIFIC MORTALITY RATES PER 100,000 POPULATION, UK (2010-2012)
FIG. 24 DRUGS IN PIPELINE
FIG. 25 TRIALS ACCORDING TO PRIMARY COMPLETION YEAR
FIG. 26 NMES AND ILES IN CRPC
FIG. 27 COMPANIES IN CRPC
FIG. 28 FAILURE RATES IN CRPC
FIG. 29 KEY FINANCIALS OF JOHNSON & JOHSNON $ MILLION (2012-2014)
FIG. 30 FINANCIAL REVENUES BY SEGMENTS (2014)
FIG. 31 FINANCIAL REVENUES BY GEOGRAPHY (2014)
FIG. 32 SWOT ANALYSIS OF JOHNSON & JOHSNON
FIG. 33 KEY FINANCIALS OF DENDREON CORPORATION $ THOUSANDS (2011-2013)
FIG. 34 FINANCIAL REVENUES BY GEOGRAPHY (2013)
FIG. 35 SWOT ANALYSIS OF DENDREON CORPORATION
FIG. 36 KEY FINANCIALS OF BAYER $ MILLIONS (2012-2014)
FIG. 37 FINANCIAL REVENUES BY SEGMENTS (2014)
FIG. 38 FINANCIAL REVENUES BY GEOGRAPHY (2014)
FIG. 39 SWOT ANALYSIS OF SANOFI
FIG. 40 KEY FINANCIALS OF BAYER $ MILLIONS (2012-2014)
FIG. 41 FINANCIAL REVENUES BY SEGMENTS (2014)
FIG. 42 FINANCIAL REVENUES BY GEOGRAPHY (2014)
FIG. 43 SWOT ANALYSIS OF BAYER
FIG. 44 KEY FINANCIALS OF ASTELLAS $ MILLIONS (2012-2013)
FIG. 45 FINANCIAL REVENUES BY GEOGRAPHY (2013)
FIG. 46 SWOT ANALYSIS OF ASTELLAS
